Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 According ... overexertion involving an outside source was ranked first ... includes injuries related to lifting, pushing, pulling, holding, ... in direct costs. The David Round Company takes ... committed to working hard to develop and design ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... April 16, 2015  Scientists from Cleave Biosciences will ... the Horizon," at the American Association for Cancer Research ... on Sunday, April 19, 2015 from 3:15pm to ... of Biology, will present new in vivo and mechanism ... inhibitor of p97, a critical enzyme that controls various ...
(Date:4/16/2015)... 16, 2015 Fairleigh Dickinson University ... Gulfo to become the Executive Director of the ... announced the kick-off of the Initiative for Patient ... Dr. Gulfo, under the Rothman Institute of Innovation ... and in collaboration with FDU’s School of Pharmacy’s ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Wis. - Commercial air service doesn't always ... viewed as more fundamental to enterprise than ever ... potential customers to dismiss the expenses of putting ... of Internet video and mixed-media communication tools. , ...
... a visit to the University of Wisconsin-Madison campus, former ... his name is under attack from critics who don't understand the ... at the annual Kastenmeier Lecture at the UW-Madison Law School ... Bayh-Dole Act , which gave universities the right to patent ...
... back, we took a look at the results of the National ... time, we saw that the Midwest had two states in the top ... top 20 states. I promised to circle back with you to review ... Midwest fared in this ranking. , ,The NIH falls under the ...
Cached Biology Technology:IP video goes where air travel cannot 2IP video goes where air travel cannot 3Landmark patent law under attack, Bayh says 2Landmark patent law under attack, Bayh says 3Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... Los Angeles, London, New Delhi, Singapore and Washington DC (July ... be advertised directly to the patient, and the results of ... the future adoption of pharmacogenetic/genomic testing, according to a position ... be published in the August 2009 issue of the ...
... many couples conceive healthy children and is generally considered ... PGD in mice suggests that this procedure may increase ... PGD is used alongside assisted reproduction technologies ... disease (e.g. Ashkenazi Jews who have a high incidence ...
... the July issue of Biomaterials , published by ... report on the first lab-grown motor nerves that are ... human body. The model system will drastically improve ... diabetic neuropathy and later, possibly multiple sclerosis (MS). In ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Preimplantation genetic diagnosis may pose neurological risks 2Researchers design first model motor nerve system that's insulated and organized like the human body 2
... 60 rabbit tissue samples arrayed on Superfrost Plus ... and 1 hematoxylin and eosin (H&E) stained slide ... tissues from 4 rabbit organisms, for a total ... sample (or core) is 1.5 mm in diameter. ...
... [6331] to Salmonella typhimurium The genus Salmonella ... genus is composed of Gram-negative bacilli that are ... antigens; the "H" or flagellar antigen (phase 1 ... of the LPS moiety) and the "Vi" or ...
A univariate (peak height or area) quantitative multi-component analysis package....
... B1 series embodies all aspects of classical ... With powerful Achromatic Super Contrast (ASC) objectives ... chip, this microscope combines flexibility and professional ... popular B1 series, the DM-B1 steps into ...
Biology Products: